TABLE 2.
Intra-class correlation (ICC) of urinary eicosanoids in participants where corticosteroid (CS) treatment was unchanged across scheduled study visits (Baseline, Visit 3 and Visit 6)
| Eicosanoid | Participants | Observations | ICC (95% CI) |
|---|---|---|---|
| PGE2; Pathway Normalised# | 298 | 536 | 0.57 (0.49–0.66) |
| TetranorPGEM | 298 | 536 | 0.57 (0.49–0.66) |
| PGD2; Pathway Normalised# | 298 | 536 | 0.51 (0.41–0.60) |
| 2,3-dinor-11β-PGF2α | 298 | 536 | 0.38 (0.27–0.48) |
| TetranorPGDM | 298 | 536 | 0.49 (0.38–0.6) |
| PGF2α; Pathway Normalised# | 298 | 536 | 0.45 (0.35–0.55) |
| PGF2α | 298 | 536 | 0.54 (0.44–0.64) |
| TetranorPGFM | 298 | 536 | 0.31 (0.20–0.42) |
| 13,14-dihydro-15-ketoPGF2α | 298 | 536 | 0.48 (0.38–0.57) |
| TXA2; Pathway Normalised# | 298 | 536 | 0.52 (0.43–0.62) |
| 11-dehydro-2,3-dinor-TXB2 | 298 | 536 | 0.39 (0.29–0.49) |
| 11-dehydroTXB2 | 298 | 536 | 0.44 (0.34–0.54) |
| 2,3-dinor-TXB2 | 298 | 536 | 0.48 (0.38–0.58) |
| Isoprostanes; Pathway Normalised# | 298 | 536 | 0.61 (0.53–0.69) |
| 8-iso-PGF2α | 298 | 536 | 0.19 (0.00–0.25) |
| 2,3-dinor-8-iso-PGF2α | 298 | 536 | 0.54 (0.45–0.63) |
| 5-iPF2α-VI | 298 | 536 | 0.64 (0.57–0.72) |
| 8,12-iso-iPF2α-VI | 298 | 536 | 0.71 (0.65–0.77) |
| CysLT; Pathway Normalised# | 298 | 536 | 0.42 (0.30–0.54) |
| LTE4 | 298 | 536 | 0.42 (0.30–0.54) |
Scheduled study visits were restricted to visits where the participant was on the same CS treatment regimen. (Confidence intervals calculated for each value). The total number of participants was n=298 with 536 observations for each mediator. PGE2: prostaglandin-E2; PGD2: prostaglandin-D2; PGF2α: prostaglandin-F2α; TXA2: thromboxane; CysLT: cysteinyl-leukotriene. #: Pathway Normalised – calculated mean of z-scores from analytes of the same pathway using log2-transformed concentrations of each individual analyte.